tradingkey.logo
搜索

直觉外科

ISRG
添加自选
374.480USD
-23.240-5.84%
收盘 08-19 16:00美东
132.51B总市值
44.77市盈率 TTM

关于 直觉外科 公司

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.

直觉外科 简介

公司代码ISRG
公司名称Intuitive Surgical Inc
上市日期Jun 13, 2000
CEORosa (David J)
员工数量15638
证券类型Ordinary Share
年结日Jun 13
公司地址1020 Kifer Road
城市SUNNYVALE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94086
电话14085232100
网址https://www.intuitive.com/en-us/about-us/company
公司代码ISRG
上市日期Jun 13, 2000
CEORosa (David J)

直觉外科公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.29M
+1.56%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.29M
+1.56%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.29M
+1.56%
Mr. David J. Rosa
Mr. David J. Rosa
Chief Executive Officer, Director
Chief Executive Officer, Director
246.80K
+0.39%
Mr. David J. Rosa
Mr. David J. Rosa
Chief Executive Officer, Director
Chief Executive Officer, Director
246.80K
+0.39%
Mr. David J. Rosa
Mr. David J. Rosa
Chief Executive Officer, Director
Chief Executive Officer, Director
246.80K
+0.39%
Dr. Craig H. Barratt, Ph.D.
Dr. Craig H. Barratt, Ph.D.
Lead Independent Director
Lead Independent Director
27.20K
+3.83%
Dr. Craig H. Barratt, Ph.D.
Dr. Craig H. Barratt, Ph.D.
Lead Independent Director
Lead Independent Director
27.20K
+3.83%
Dr. Craig H. Barratt, Ph.D.
Dr. Craig H. Barratt, Ph.D.
Lead Independent Director
Lead Independent Director
27.20K
+3.83%
Johnson (Amal M)
Johnson (Amal M)
Independent Director
Independent Director
13.54K
+3.92%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.29M
+1.56%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.29M
+1.56%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.29M
+1.56%
Mr. David J. Rosa
Mr. David J. Rosa
Chief Executive Officer, Director
Chief Executive Officer, Director
246.80K
+0.39%
Mr. David J. Rosa
Mr. David J. Rosa
Chief Executive Officer, Director
Chief Executive Officer, Director
246.80K
+0.39%
Mr. David J. Rosa
Mr. David J. Rosa
Chief Executive Officer, Director
Chief Executive Officer, Director
246.80K
+0.39%

常见问题

直觉外科的前五大股东是谁?

直觉外科 的前五大股东如下:Dr. Gary S. Guthart, Ph.D.

有多少机构持有直觉外科(ISRG)的股份?

截至2026Q1,共有3941家机构持有直觉外科的股份,合计持有的股份价值约为316.11M,占公司总股份的89.25%。与2025Q4相比,机构持股有所增加,增幅为-2709007.00。

哪个业务部门对直觉外科的收入贡献最大?

在2026Q1,Instruments and accessories业务部门对直觉外科的收入贡献最大,创收6.02B,占总收入的59.80%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有